個別化醫療的商業策略整合

個別化醫療的商業策略整合 是由出版商Decision Resources, Inc.在2008年09月所出版的。 這份英文市場調查報告書包含37 Pages 價格從美金2250起跳。

簡介

目錄

Abstract

Introduction

A growing awareness is taking hold across the pharmaceutical industry: what was once impossible - tailoring treatment to specifi c groups of patients rather than to the population as a whole - is becoming possible. What is needed to integrate a personalized medicine approach into business strategies? We provide perspectives from pharmaceutical, diagnostic, and managed care executives and create a set of recommendations based on what experts advise when contemplating the operational shift to the delivery of personalized healthcare.

Get the Answers You Need to Shape Your Strategy

• Lilly has said it needs to transform every part of its operations. How is Lilly working to integrate a personalized medicine approach into its business strategies? What is entailed in the company' s cultural and organizational restructuring and its new FIPNet model?
• Roche completed a hostile takeover of Ventana and announced its intention to assume complete control of Genentech. Why are these two strategic maneuvers so important to Roche and why are they important to integrating personalized medicine strategies more tightly into the company' s operations? Does personalized medicine success require that a company consume its diagnostic or targeted therapy partner outright and own it lock, stock, and barrel?
• The pharmaceutical industry has adopted formularies and benefi t plan designs to differentiate drugs. What are the problems covering and reimbursing genetic testing and pharmacodiagnostic tests? What problems continue to plague gene-based testing and value-added reimbursement?

Scope

• Business models and strategies: FIPNet, outsourcing, precompetitive collaboration, personalized medicine, fully integrated pharmaceutical company (FIPCO), virtual companies, nichebusters, operational effi ciencies, cost-cutting, mega-mergers, consolidation, control versus ownership, decentralized management, hub and spoke business.
• Diagnostic issues: Trends in genetic tests and genetic testing, improving the predictability of biomarker discovery, standardizing biomarkers, analytic validity, clinical utility, clinical validity, integrating diagnostic development into clinical development, fl uorescence imaging, molecular diagnostics, gene profi ling, biological signatures, tissue-based diagnostics.
• Pharmaceutical issues: Tailored therapies, disease biology areas, deal making, innovation, information fl ow and unfettered access to research, nichebusters, patient phenotypes, health outcomes, value-for-money.
• RxDx partnership issues: Adequate control of intellectual property, structuring the relationship, structuring the deal, what to look for in a diagnostic partner.
• Managed care issues: Value-added reimbursement, revamping CPT codes, cost-containment, evidentiary-based review, health policy technology assessments, physician and patient education strategies, direct-to-consumer marketing.
• Two Spectrum, Personalized Medicine Scorecards: Executive insights from transcripts of Lilly and Roche company presentations to investors.
• Expert commentaries: Executives from Iris BioTechnologies, Roche, and VisEn Medical share their insights on genetic tests, targeted therapies, personalized medicine development, transitioning from research to the clinic, and healthcare coverage and reimbursement.
• Interviews: Senior directors from two health benefi t insurers share their insights on genetic and pharmacogenomic tests, evidence-based review, coding, and reimbursement issues.

Mentioned in this Spectrum Report

Companies and Organizations

• 454 Life Sciences
• Abbott
• Affymetrix
• Agendia
• Alnylam Pharmaceuticals
• Ambrx
• American College of Obstetricians/Gynecologists
• American Diabetes Association
• American Medical Association
• Amgen
• Arius Research
• Aveo Pharmaceuticals
• Baylor University
• Biosite
• BioVeris
• Blue Cross Blue Shield
• Centers for Disease Control and Prevention
• Chugai
• Daiichi Sankyo
• Eli Lilly and Company
• Enlight Biosciences
• Entelos
• Evaluation of Genomic Applications in Practice and
• Prevention
• Fox Chase Cancer Center
• GE Healthcare
• Genentech
• Genomic Health
• HealthLeaders InterStudy
• Hoffmann-La Roche
• Iris BioTechnologies
• Johnson & Johnson
• Juvenile Diabetes Research Foundation
• Massachusetts General Hospital
• Merck & Co.
• Mirus Bio
• NimbleGen Systems
• Olympus Medical Systems
• Pfi zer
• Piramed
• PureTech Ventures
• Roche Diagnostics
• Roche Group
• Roche Pharmaceuticals
• Sanford University
• Technical University
• Therapeutic Human Polyclonals
• Translational Genomics Research Institute
• University of Michigan
• Ventana Medical Systems
• VisEn Medical
• WellPoint
• WellPoint Health Networks

Table of Contents

Executive Summary

• Strategic Considerations
• Stakeholder Implications

Introduction

Expert Commentary - Translating Technologies from Preclinical Applications into Clinical Medicine

• The Need to Better Understand Disease Processes
• Improving the Predictability of Biomarker Discovery
• Structuring the DxRx Partnership

Expert Commentary - Integrating Molecular Diagnostics with Personalized Lifestyle Therapies The Multiple Marker Approach

• Integrating Diagnostic Development into Clinical Trials
• The Value-Added Proposition

Lilly Case Study - Developing the Corporate Mind-Set for Personalized Medicine

• Personalized Drug Development
• Prasugrel, an Antiplatelet Drug in Development with Daiichi Sankyo
• Alimta for Mesothelioma and Non-Small-Cell Lung Cancer
• Disease-Modifying Therapies for Alzheimer' s Disease
• Biomarker Study for Xigris
• Cancer AKT1 Biomarker Study
• Molecular Diagnostic and Tailored Therapy Deals
• Integrating a Tailored Medicine Approach into Lilly' s Business Strategies

Roche Case Study - Breaking Down the Barriers

• Personalized Healthcare
• Roche 2015
• What Is Right for the Time
• Moving Away from a Fully Integrated Pharmaceutical Company (FIPCO) Model
• Strengthening the Tie Between Rx and Dx
• Control vs Ownership - Effect on Intellectual Property
• Take-Home Lesson for Other Companies Intending to Work in the Personalized
• Medicine Space

Expert Commentary - Roche Perspectives on How to Integrate Personalized

• Medicine Strategies
• Realistic Expectations and Misperceptions
• Nichebusters - A Fairly New Concept
• Misperceptions
• Integrating Diagnostics into Drug Development
• Stumbling Blocks
• Understanding Cost-Time Expectations
• What to Look for in a Diagnostics Partner
• Resolving Intellectual Property Issues: Who Will Own What?
• Structuring the Relationship
• Structuring the Deal

Genetic Test Coverage and Value-Added Coding

• Types of Genetic Tests
• Need for Coding System Changes

Trends in Genetic Testing and Value-Added Reimbursement

• Revamp Coding and Create Value-Based Reimbursement
• Manage the Cost with Evidence-Based Processes
• Assess Technology to Determine Coverage
• Better Educate - A Genetic Counseling Program

Checklist of Recommendations

Experts

• Finley Austin, Ph.D., Head, U.S. External Research & Innovation Environment, Roche
• Simon Chin, M.B.A., CEO, Iris BioTechnologies
• Kirtland Poss, President and CEO, VisEn Medical Alan B. Rosenberg, M.D., Vice President of Medical Policy, Technology Assessment, and Credentialing Programs, WellPoint

Expert Commentaries

• Translating Technologies from Preclinical Applications into Clinical Medicine
• Integrating Molecular Diagnostics With Personalized Lifestyle Therapies
• Roche Perspectives on How to Integrate Personalized Medicine Strategies

Interviews

• Genetic Test Coverage and Value-Added Coding
• Trends in Genetic Testing and Value-Added Reimbursement

Case Studies

• Lilly - Developing the Corporate Mindset for Personalized Medicine
• Roche - Breaking Down the Barriers

Tables

• 1. Deals to Facilitate Lilly' s Tailored Therapy Strategies
• 2. Roche Deals to Strengthen Its Position in Personalized Medicine Development, 2007-2008

Figures

• 1. Implementing Eli Lilly and Company' s Transformational FIPNet and Personalized Medicine Business Model
• 2. Roche 2015: Strategic Priorities for Innovation and Long-Term Growth

Spectrum, Personalized Medicine Scorecards

• Eli Lilly & Company Executives Speak Out.
• Roche Executives Speak Out

相關商品

個人化醫學相關市場調查報告書

個別化醫療：科學的・商業的情勢
Personalized Medicine - scientific & commercial aspects
價格 : US $ 5000
出版日期 : 2012年01月

定點醫療診斷檢査動向
Point of Care Diagnostic Testing Sector Trends
價格 : US $ 3400
出版日期 : 2011年11月

歐洲的重點照護診斷檢查市場
European Point of Care Diagnostic Testing Markets
價格 : US $ 3400
出版日期 : 2011年09月

Decision Resources, Inc.發行的生物科技相關市場調查報告書

以生物標記來預測自體免疫疾病生物療法的反應

Special Report: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases

價格 : US $ 9200

出版日期 : 2011年06月

成為下一波一鳴驚人藥物的新一代治療用抗體的尋求

Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs

價格 : US $ 4600

出版日期 : 2011年06月

探索讓個人化醫療進化的資訊技術工具

Exploiting Information Technology Tools to Advance Personalized Medicine

價格 : US $ 4600

出版日期 : 2011年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!